The European Union has affirmed the utilization of remdesivir to treat serious cases of Coronavirus.
The declaration was made on Friday July 3, days after the US successfully stored the world’s whole supply of the antiviral drug. Its endorsement came after two significant US studies indicated that remdesivir can diminish the duration of hospital stay for COVID-19 patients.
EU Health Commissioner Stella Kyriakides said in an announcement;
“Today’s authorisation of a first medicine to treat COVID-19 is an important step forward in the fight against this virus.
“We are granting this authorisation less than a month after the application was submitted, showing clearly the EU’s determination to respond quickly whenever new treatments become available.”
Remdesivir which is the main anti-coronavirus drug to be given the green light in the EU, was initially proposed as a treatment for Ebola. It was affirmed in UK toward the ending of May, with health authorities outlining that it would just be utilized to treat the most diseased patients. It is one of two medications affirmed in Britain to treat COVID-19, the other being a modest steroid called dexamethasone.